Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer.

bioRxiv : the preprint server for biology·2026
Same author

The oxidative phosphorylation inhibitor, atovaquone, upregulates PD-L1 via activation of the ATM/ATR DNA damage response pathway.

Research square·2026
Same author

Extracellular vesicles mediate intercellular transfer of PD-L1 and bystander T-cell suppression.

Cellular and molecular life sciences : CMLS·2026
Same author

Regulatory B cell CCL3 competency promotes disease resolution and oligodendrogenesis in experimental autoimmune encephalomyelitis.

Communications biology·2025
Same author

Synthesis of mRNA lipid nanoparticles for engineering GD2 CAR T and CAR NK cells against neuroblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Standardized Isolation and Cytokine Priming of Murine Bone Marrow-Derived Mesenchymal Stromal Cells for Enhanced Immunomodulation.

Journal of visualized experiments : JoVE·2025

Related Experiment Video

Updated: Apr 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

B cells for cancer immunotherapy.

Jiusheng Deng1, Jacques Galipeau2

  • 1Department of Hematology and Medical Oncology; Winship Cancer Institute; Emory University ; Atlanta, GA USA.

Oncoimmunology
|May 6, 2015
PubMed
Summary

Researchers engineered a novel fusion cytokine, GIFT4, from granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). This cytokine enhances B cells to create a potent cancer immunotherapy.

Keywords:
B cellsGIFT4cancer immunotherapyfusion cytokine

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Related Experiment Videos

Last Updated: Apr 13, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Area of Science:

  • Immunology
  • Biotechnology
  • Cancer Research

Background:

  • B cells are crucial immune cells with potential in cancer therapy.
  • Current immunotherapies face challenges in efficacy and specificity.

Purpose of the Study:

  • To engineer a novel fusion cytokine, GIFT4, to enhance B cell-mediated anti-tumor immunity.
  • To evaluate the potential of GIFT4-programmed B cells as a cancer immunotherapeutic strategy.

Main Methods:

  • Fusion cytokine engineering combining GM-CSF and IL-4 into GIFT4.
  • In vitro and in vivo studies to assess GIFT4's effects on B cells.
  • Evaluation of GIFT4-programmed B cells' capacity to induce tumoricidal responses.

Main Results:

  • GIFT4 demonstrated robust gain-of-function immunostimulatory effects on B cells.
  • GIFT4-programmed B cells exhibited a unique cellular identity.
  • These modified B cells showed a potent capacity to elicit a tumoricidal cell response.

Conclusions:

  • GIFT4 represents a novel tool for enhancing B cell function.
  • GIFT4-programmed B cells offer a promising new avenue for B cell-based cancer immunotherapy.